Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3750475 | 0.98 | TAAR1 (0.58) | TAAR1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL6562809 | 0.87 | TAAR1 (0.75) | TAAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL6563360 | 0.85 | TAAR1 (0.71) | TAAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29570669 | 0.82 | KIF11 (0.47) | TAAR1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL5877849 | 0.80 | TAAR1 (0.65) | TAAR1SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL10961852 | 0.80 | TAAR1 (0.65) | TAAR1CYP3A4MAPTKIF11 | |
| SCHEMBL10574062 | 0.78 | TAAR1 (0.62) | TAAR1MEN1KMT2ATSHRCYP1A2 | |
| SCHEMBL10837089 | 0.78 | MEN1 (0.52) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8350486 | 0.78 | TAAR1 (0.62) | TAAR1HTR2AHTR2BTSHRCYP1A2 | |
| SCHEMBL12171 | 0.78 | TAAR1 (0.62) | TAAR1CYP3A4MAPTKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572337-B2 | Antibacterial agents: arylalkylcarboxamido phloroglucinols | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210017126-A1 | Antibacterial Agents: Arylalkylcarboxamido Phloroglucinols | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-01-21 | — | — | US | disclosed |
| EP-2782565-B1 | USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES | BAYER IP GMBH (DE) | 2019-11-06 | — | — | EP | disclosed |
| EP-2782565-B1 | USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES | BAYER IP GMBH (DE) | 2019-11-06 | — | — | EP | disclosed |
| US-9422276-B2 | Use of aryl and hetaryl carboxamides as endoparasiticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422276-B2 | Use of aryl and hetaryl carboxamides as endoparasiticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422276-B2 | Use of aryl and hetaryl carboxamides as endoparasiticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| CN-104203223-A | Use of aryl and hetaryl carboxamides as endoparasiticides | BAYER IP GMBH | 2014-12-10 | — | — | CN | disclosed |
| US-20140323736-A1 | USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323736-A1 | USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | disclosed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | disclosed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| US-4600705-A | Gonadoliberin derivatives containing a β-aspartyl group, a process for the preparation thereof and pharmaceutical preparations containing them | Richter Gedeon Veyteszeti Gyar R.T. (HU) | 1986-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | TAAR1 80/4885MEN1 685/4885KMT2A 2666/4885 |
| US-11572337-B2 | Antibacterial agents: arylalkylcarboxamido phloroglucinols | RNGTT, FBL, POLR1C | TAAR1 4283/4885MEN1 4099/4885KMT2A 1741/4885 |
| US-20140323736-A1 | USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES | AADAC, ENPP2, EPX | TAAR1 1744/4885MEN1 3156/4885KMT2A 2138/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | TAAR1 2804/4885MEN1 1931/4885KMT2A 1276/4885 |
| US-20210017126-A1 | Antibacterial Agents: Arylalkylcarboxamido Phloroglucinols | RNGTT, FBL, POLR1C | TAAR1 4283/4885MEN1 4099/4885KMT2A 1741/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | TAAR1 2804/4885MEN1 1931/4885KMT2A 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.